Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Net Recovery pitches FDA‑cleared neuroelectric device to Lexington commission, seeks pilot funding for jails
Summary
Net Recovery presented an FDA‑cleared neuroelectric therapy (NET) device to the Lexington Opioid Abatement Commission, describing trial results that reduced withdrawal and cravings and asking local governments to consider paying for pilot treatment in detention centers with opioid‑settlement funds.
Jeff Lott, communications director for Net Recovery, presented the company’s neuroelectric therapy (NET) device to the Lexington Opioid Abatement Commission and described clinical results and ongoing county partnerships.
Lott said the device — a patient‑controlled stimulator worn with electrodes behind the ears — received full FDA clearance in 2024 after a randomized, double‑blind trial completed in 2023 involving about 108 participants. He told the commission the trial showed rapid reductions in withdrawal measures and cravings for many participants and that patients who used the device more than 24 hours were more likely to remain in residential levels of care during the study.
Lott described specific outcome measures from the company’s trial and follow‑up work: he said a very high…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
